Malign pleural mesothelioma – so far an undefeated tumor


Authors: Vítězslav Kolek
Authors‘ workplace: Klinika plicních nemocí a tuberkulózy LF UP a FN Olomouc
Published in: Vnitř Lék 2017; 63(11): 884-888
Category: Reviews

Overview

Malign pleural mesothelioma is the most frequent primary tumor of the pleura of high aggressiveness. Its most frequent cause is contact with asbestos and, although working with asbestos is already prohibited in developed countries, its incidence is on the increase so far. Diagnostics primarily considers anamnesis, clinical symptoms and immunohistochemical examination of a tumor sample. The basic therapy used over the past 10 years is chemotherapy with cisplatin – pemetrexed combinations. Numerous studies are going on with a different biologically targeted therapy, immunotherapy and other drugs which may improve patients’ prognosis. The surgical approach is limited by a suitable choice of patients and sufficient experience of the medical center. Extrapleural pneumonectomy or extended pleurectomy are performed. However even the combined therapy with adjuvant or neoadjuvant chemotherapy or radiotherapy has not considerably extended survival.

Key words:
diagnostics – epidemiology – malign pleural mesothelioma – therapy


Sources

1. Robinson BWS, Musk AW, Lake RA. Malignant mesothelioma. Lancet 2005; 366(9483): 397–408.

2. Scherpereel A, Astoul P, Baas P et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J, 2010; 35(3): 479–495. Dostupné z DOI: <http://dx.doi.org/10.1183/09031936.00063109>.

3. WAGNER JC et al. Asbestos Dust and Malignancy. Proceedings of the XIV International Conference of Occupational Health, Madrid, 1963. Excerpta Medica: 1066–1067.

4. Sahin AA, Coplu L, Selcuk ZT et al. Malignant pleural mesothelioma caused by environmental exposure to asbestos or erionite in rural Turkey: cT findings in 84 patients. AJR Am J Roentgenol 1993; 161(3): 533–537.

5. Jasani B, Gibbs A. Mesothelioma not associated with asbestos exposure. Arch Pathol Lab Med 2012; 136(3): 262–267. Dostupné z DOI: <http://dx.doi.org/10.5858/arpa.2011–0039-RA>.

6. Kolek V, Fialová J, Petřek M et al. Význam sledování alveolárních změn u pracovníků s azbestem. Prac Lék 1996; 48(2): 79–84.

7. Palatka K, Kolek V, Tichý T et al. Zkušenosti s diagnostikou a léčbou maligního mezoteliomu, srovnání období 1990–1999 a 2000–2004. Stud Pneumol Phthiseol 2007; 67(5): 188–193.

8. Nishikawa K, Takahashi K, Karjalainen A et al. Recent mortality from pleural mesothelioma, historical patterns of asbestos use, and adoption of bans: a global assessment. Environ Health Perspect 2008; 116(12): 1675–1680. Dostupné z DOI: <http://dx.doi.org/10.1289/ehp.11272>.

9. Maeda M, Hino O. Molecular tumor markers for asbestos-related mesothelioma: Serum diagnostic markers. Pathol Int 2006; 56(11): 649–654.

10. Jakubec P, Pelclova D, Smolkova P et al. Significance of serum mesothelin in an asbestos-exposed population in the Czech Republic. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2015; 159(3): 472–479.

11. Cui A, Jin XG, Zhai K et al. Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis. BMJ Open 2014; 4(2): e004145. Dostupné z DOI: <http://dx.doi.org/10.1136/bmjopen-2013–004145>.

12. Van der Bij S, Schaake E, Koffijberg H et al. Markers for the non-invasive diagnosis of mesothelioma: a systematic review. Br J Cancer 2011; 104(8): 1325–1333. Dostupné z DOI: <http://dx.doi.org/10.1038/bjc.2011.104>.

13. Mossman BT, Shukla A, Heintz NH et al. New Insights into Understanding the Mechanisms, Pathogenesis, and Management of Malignant Mesotheliomas. Am J Pathol 2013; 182(4): 1065–1077. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ajpath.2012.12.028>.

14. Galateau-Salle F, Churg A, Roggli V et al. [World Health Organization Committee for Tumors of the Pleura[. The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification. J Thorac Oncol 2015; 11(2): 142–154. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jtho.2015.11.005>.

15. Goto Y, Shinjo K, Kondo Y et al. Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma. Cancer Res 2009; 69(23): 9073–9082. Dostupné z DOI: <http://dx.doi.org/10.1158/0008–5472.CAN-09–1595>.

16. Testa JR, Cheung M, Pei J et al. BAP1 mutations predispose to malignant mesothelioma. Nat Genet 2011; 43(10): 1022–1025. <http://dx.doi.org/10.1038/ng.912>.

17. Yokoyama T, Osada H, Murakami H et al. YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation. Cancerogenesis 2008; 29(11): 2045–2052. Dostupné z DOI: <http://dx.doi.org/10.1093/carcin/bgn184>.

18. Vogelzang NJ, Rusthoven J, Symanowski J et al. A phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21(14): 2636–2644.

19. Zauderer MG, Kass SL, Woo K el al. Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma Lung Cancer 2014; 84(3): 271–274. Dostupné z DOI: <http://dx.doi.org/10.1016/j.lungcan.2014.03.006>.

20. Sugarbaker DJ, Flores RM, Jaklitsch MT et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. Thorac Cardiovasc Surg 1999; 117(1): 54–63.

21. Cao CQ, Yan TD, Bannon PG et al. A systematic review of extrapleural pneumonectomy for malignant pleural mesothelioma. J Thorac Oncol 2010; 5(10): 1692–1703. Dostupné z DOI: <http://dx.doi.org/10.1097/JTO.0b013e3181ed0489>.

22. Opitz I. Management of malignant pleural mesothelioma – The European experience. J Thorac Dis 2014; 6(Suppl 2): S238-S252. <http://dx.doi.org/10.3978/j.issn.2072–1439.2014.05.03>.

23. Tilleman TR, Richards WG, Zellos L et al. Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study. J Thorac Cardiovasc Surg 2009; 138(2): 405–441. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jtcvs.2009.02.046>.

24. de Perrot M, Feld R, Cho BC et al. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol 2009; 27(9): 1413–1418. <http://dx.doi.org/10.1200/JCO.2008.17.5604>.

25. Krug LM, Kindler H, Calvert H et al. VANTAGE 014: vorinostat (V) in patients with advanced malignant pleural mesothelioma (MPM) who have failed prior pemetrexed and either cisplatin or carboplatin therapy: a phase III, randomized, double-blind, placebo-controlled trial [abstract 3BA]. Eur J Cancer 2011; 47(Suppl 2): 2–3. Dostupné z DOI: <http://dx.doi.org/10.1016/S0959–8049(11)70098–3>.

26. Zalcman G, Mazières J, Margery J et al. Bevacizumab 15 mg/kg plus cisplatin-pemetrexed (CP) triplet versus CP doublet in Malignant Pleural Mesothelioma (MPM): Results of the IFCT-GFPC-0701 MAPS randomized phase 3 trial. ASCO Annual Meeting. Journal of Clinical Oncology 2015; 33(15 Suppl): 7500. Dostupné z DOI: <http://dx.doi.org/10.1200/jco.2015.33.15_suppl.7500>.

27. Ramalingam SS, Belani CP, Ruel C et al. Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J Thorac Oncol 2009; 4(1): 97–101. Dostupné z DOI: <http://dx.doi.org/10.1097/JTO.0b013e318191520c>.

28. Scagliotti GV, Gaafar RM, Nowak AK et al. Lume-meso: A double-blind, randomized, phase II/III study of nintedanib (N) + pemetrexed (P)/cisplatin (C) followed by maintenance N versus placebo + P/C followed by maintenance placebo for patients with unresectable malignant pleural mesothelioma (MPM). J Clin Oncol 2016; 34(15 Suppl): abstr. TS8574. Dostupné z DOI: <http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.TPS8574>.

29. Christmas TI, Manning LS, Garlepp MJ et al. Effect of interferon alfa 2a on malignant mesothelioma. J Interferon Res 1993; 13(1): 9–12.

30. Astoul P, Picat-Joossen D, Viallat JR et al. Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a phase II study. Cancer 1998; 83(10): 2099–2104.

31. Schwarzenberger P, Harrison L, Weinacker A et al. The treatment of malignant pleural mesothelioma with gene modified cancer cells: a phase I study. Hum Gene Ther 1998; 9(17): 2641–2649.

32. Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res 2004; 10(12 Pt 1): 3937–3942.

33. Alley EW, Schellens JH, Santoro A et al. Single-Agent Pembrolizumab for Patients with Malignant Pleural Mesothelioma (MPM). International Association for the Study of Lung Cancer, 2015. 16th World Conference on Lung Cancer. ORAL 11.03.

34. Remon J, Reguart N, Corral J et al. Malignant pleural mesothelioma: New hope in the horizon with novel therapeutic strategies. Cancer Treat Rev 2015; 41(1): 27–34. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ctrv.2014.10.007>.

35. Kolek V, Havel L, Pešek M et al. Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma – Czech Experience. J Thorac Oncol 2015; 9(Suppl 2): 747. (P3.08–010).

Labels
Diabetology Endocrinology Internal medicine

Article was published in

Internal Medicine

Issue 11

2017 Issue 11

Most read in this issue

This topic is also in:


Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account